Jonathan A Fletcher

List of Publications by Year
in descending order

70	5,147	109137	123241
papers	citations	35 h-index	61 g-index

74	74	74	6102
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature, 1992, 356, 713-715.	13.7	653
2	PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nature Genetics, 2014, 46, 1227-1232.	9.4	472
3	The Clinicopathologic Features of YWHAE-FAM22 Endometrial Stromal Sarcomas. American Journal of Surgical Pathology, 2012, 36, 641-653.	2.1	265
4	14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 929-934.	3.3	239
5	Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish. Cell, 2019, 177, 1903-1914.e14.	13.5	188
6	Cyclin D1 as a Diagnostic Immunomarker for Endometrial Stromal Sarcoma With YWHAE-FAM22 Rearrangement. American Journal of Surgical Pathology, 2012, 36, 1562-1570.	2.1	184
7	Various regions within the alpha-helical domain of theCOL1A1 gene are fused to the second exon of thePDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas. , 1998, 23, 187-193.		158
8	A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nature Genetics, 2014, 46, 595-600.	9.4	152
9	Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nature Genetics, 2014, 46, 601-606.	9.4	142
10	Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients. Clinical Cancer Research, 2014, 20, 5745-5755.	3.2	137
11	Characterization of the chromosomal translocation t(10;17)(q22;p13) in clear cell sarcoma of kidney. Journal of Pathology, 2012, 227, 72-80.	2.1	125
12	BCOR Internal Tandem Duplication in High-grade Uterine Sarcomas. American Journal of Surgical Pathology, 2018, 42, 335-341.	2.1	118
13	KIT Mutations in GIST. Current Opinion in Genetics and Development, 2007, 17, 3-7.	1.5	114
14	Cytogenetic evidence of clonality in a case of pigmented villonodular synovitis. Cancer, 1991, 67, 121-125.	2.0	113
15	Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. British Journal of Cancer, 2019, 120, 612-620.	2.9	109
16	Upper respiratory tract carcinoma with chromosomal translocation 15;19. Cancer, 2001, 92, 1195-1203.	2.0	102
17	Classification of human liposarcoma and lipoma using ex vivo proton NMR spectroscopy. Magnetic Resonance in Medicine, 1999, 41, 257-267.	1.9	90
18	Trisomy 5 and trisomy 7 are nonrandom aberrations in pigmented villonodular synovitis: Confirmation of trisomy 7 in uncultured cells. Genes Chromosomes and Cancer, 1992, 4, 264-266.	1.5	88

#	Article	IF	Citations
19	Variant translocations involving 16q22 and 17p13 in solid variant and extraosseous forms of aneurysmal bone cyst. , 2000, 28, 233-234.		88
20	Cytogenetic findings in pediatric adipose tumors: Consistent rearrangement of chromosome 8 in lipoblastoma. Genes Chromosomes and Cancer, 1993, 6, 24-29.	1.5	87
21	Role of KIT and platelet-derived growth factor receptors as oncoproteins. Seminars in Oncology, 2004, 31, 4-11.	0.8	75
22	Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma. Cancer Research, 2016, 76, 319-328.	0.4	73
23	Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results. JAMA Oncology, 2017, 3, 944.	3.4	73
24	Frequent expression of KIT in endometrial stromal sarcoma with YWHAE genetic rearrangement. Modern Pathology, 2014, 27, 751-757.	2.9	71
25	Targeting the c-Kit Promoter G-quadruplexes with 6-Substituted Indenoisoquinolines. ACS Medicinal Chemistry Letters, 2010, 1, 306-310.	1.3	67
26	Alternate <scp>PAX</scp>3â€<scp>FOXO</scp>1 oncogenic fusion in biphenotypic sinonasal sarcoma. Genes Chromosomes and Cancer, 2016, 55, 25-29.	1.5	67
27	Cytogenetic and histologic findings in 17 pulmonary chondroid hamartomas: Evidence for a pathogenetic relationship with lipomas and leiomyomas. Genes Chromosomes and Cancer, 1995, 12, 220-223.	1.5	66
28	Cardiac synovial sarcoma with translocation (X; 18) associated with asbestos exposure. Cancer, 1994, 73, 74-78.	2.0	64
29	Clonal 6p21 rearrangement is restricted to the mesenchymal component of an endometrial polyp. Genes Chromosomes and Cancer, 1992, 5, 260-263.	1.5	63
30	Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget, 2016, 7, 16581-16592.	0.8	57
31	MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nature Communications, 2017, 8, 14674.	5.8	53
32	Mesenchymal tumors of the gastrointestinal tract with NTRK rearrangements: a clinicopathological, immunophenotypic, and molecular study of eight cases, emphasizing their distinction from gastrointestinal stromal tumor (GIST). Modern Pathology, 2021, 34, 95-103.	2.9	52
33	KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation. Journal of Clinical Oncology, 2015, 33, e93-e96.	0.8	48
34	Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy. Cancer Cytopathology, 2018, 126, 552-566.	1.4	48
35	Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain. Cancer Discovery, 2021, 11, 108-125.	7.7	47
36	Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy. Clinical Cancer Research, 2014, 20, 6071-6082.	3.2	45

#	Article	IF	Citations
37	CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans. Molecular Cancer Therapeutics, 2015, 14, 1346-1353.	1.9	44
38	Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line. Laboratory Investigation, 2016, 96, 1128-1137.	1.7	31
39	Mutational inactivation of mTORC1 repressor gene DEPDC5 in human gastrointestinal stromal tumors. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22746-22753.	3.3	29
40	Targeting SALL4 by entinostat in lung cancer. Oncotarget, 2016, 7, 75425-75440.	0.8	29
41	Comparison between the in vitro intrinsic radiation sensitivity of human soft tissue sarcoma and breast cancer cell lines. , 1996, 61, 290-294.		28
42	Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. Oncologist, 2015, 20, 823-830.	1.9	26
43	Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs). Clinical Sarcoma Research, 2019, 9, 3.	2.3	26
44	Translocation (I2;22)(q13â€“I4;q I 2) is a nonrandom aberration in soft-tissue clear-cell sarcoma. Genes Chromosomes and Cancer, 1992, 5, 184-184.	1.5	25
45	Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumors. Oncotarget, 2014, 5, 4071-4086.	0.8	24
46	Translocation t(8;13)(p11;q11-12) in stem cell leukemia/lymphoma of t-cell and myeloid lineages. Genes Chromosomes and Cancer, 1995, 12, 148-151.	1.5	23
47	Human pancreatic cancer cells (MPANC-96) recognized by autologous tumor-infiltrating lymphocytes afterin vitro as well asin vivo tumor expansion. , 1997, 71, 993-999.		23
48	KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors â€” TORC1/2 Inhibition as Salvage Strategy. Molecular Cancer Therapeutics, 2019, 18, 1985-1996.	1.9	22
49	Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence. Oncogene, 2019, 38, 6615-6629.	2.6	21
50	Identification of a YAC spanning the translocation breakpoint t(8;22) associated with acute monocytic leukemia. , 1996, 15, 191-194.		20
51	Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5746-E5755.	3.3	20
52	E3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in nonâ€“small cell lung cancer. Journal of Experimental Medicine, 2021, 218, .	4.2	18
53	LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma. Oncogene, 2019, 38, 1200-1210.	2.6	16
54	Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas. Cancer, 2021, 127, 2666-2673.	2.0	15

#	Article	IF	Citations
55	Inhibition of KIT-Glycosylation by 2-Deoxyglucose Abrogates KIT-Signaling and Combination with ABT-263 Synergistically Induces Apoptosis in Gastrointestinal Stromal Tumor. PLoS ONE, 2015, 10, e0120531.	1.1	14
56	PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. Cancer Discovery, 2022, 12, 2120-2139.	7.7	14
57	Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy. British Journal of Cancer, 2016, 114, 1219-1226.	2.9	13
58	Molecular biology and cytogenetics of soft tissue sarcomas: Relevance for targeted therapies. , 2004, 120, 99-116.		13
59	Identification of genetically aberrant cell lineages in Wilms' tumors. Genes Chromosomes and Cancer, 1994, 10, 40-48.	1.5	12
60	YWHAE-NUTM2 oncoprotein regulates proliferation and cyclin D1 via RAF/MAPK and Hippo pathways. Oncogenesis, 2021, 10, 37.	2.1	11
61	Conjoined hyperactivation of the RAS and PI3K pathways in advanced GIST.. Journal of Clinical Oncology, 2016, 34, e22520-e22520.	0.8	7
62	Overcoming heterogenity in imatinib-resistant gastrointestinal stromal tumor. Oncotarget, 2019, 10, 6286-6287.	0.8	7
63	Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers. Clinical Cancer Research, 2022, 28, 1268-1276.	3.2	7
64	BPR 1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor. Cancer Science, 2018, 109, 3591-3601.	1.7	5
65	Identification of phenothiazine as an ETV1â€‘targeting agent in gastrointestinal stromal tumors using the Connectivity Map. International Journal of Oncology, 2019, 55, 536-546.	1.4	3
66	Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). , 0, .		1
67	Phase Ib study of rapid alternation of sunitinib (SU) and regorafenib (RE) in patients (pts) with advanced gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology, 2018, 36, 11510-11510.	0.8	1
68	ZMYM2-FGFR1 fusion as secondary change in acute myeloid leukemia. Leukemia and Lymphoma, 2019, 60, 556-558.	0.6	0
69	LMTK3 to regulate the translation of oncogenic KIT in GIST regardless of imatinib sensitivity.. Journal of Clinical Oncology, 2018, 36, 11535-11535.	0.8	0
70	Abstract 5648: Response and resistance to CDK2 and CDK4/6 inhibition in GIST. Cancer Research, 2022, 82, 5648-5648.	0.4	0